Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
What Is Hidden Behind ‘Low-Cost CAR-T’? Global Regulators Are Cracking Down
July 11, 2026
Learn why global regulators are cracking down on low-cost CAR-T therapy programs, the hidden risks behind gray-market cell therapies, and how patients can identify legitimate CAR-T treatment providers.
What Increases the Risk of Brain Tumors? Understanding the Main Risk Factors
July 10, 2026
Learn the major risk factors for brain tumors, including ionizing radiation, inherited genetic syndromes, age, family history, immune dysfunction, and the latest advances in brain tumor risk prediction and precision medicine.
Why Does the Epstein-Barr Virus Cause Nasopharyngeal Carcinoma? Understanding High-Risk Factors and Early Warning Signs
July 09, 2026
Learn how Epstein-Barr virus (EBV) contributes to nasopharyngeal carcinoma (NPC), discover high-risk factors, early warning signs, screening methods, and the latest advances in precision medicine and innovative therapies.
Which GBM Patients May Benefit from Bevacizumab?
July 08, 2026
Learn which glioblastoma (GBM) patients may benefit from bevacizumab, its clinical benefits, treatment approaches, side effects, and role in recurrent GBM management.
Follicular Lymphoma Treatment Enters the Immunotherapy Era: Bispecific Antibodies Are Rising
July 08, 2026
Why Are More Cancer Drugs Becoming Oral Therapies? The Current Landscape of Oral Targeted Therapy in China
July 08, 2026
Explore why oral targeted therapies are transforming modern oncology, how China’s innovative pharmaceutical industry is driving this shift, and what it means for long-term cancer management and international patients.
A Milestone for Targeted Protein Degradation: The World’s First PROTAC Drug Approved
July 06, 2026
The U.S. FDA has approved Vepdegestrant (Veppanu), the world’s first PROTAC therapy, for ER-positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer—marking a historic milestone for targeted protein degradation.
What Is the Difference Between Nasopharyngeal Cancer, Oropharyngeal Cancer, and Laryngeal Cancer? Understanding the Key Differences Among Three Head and Neck Cancers
July 03, 2026
Learn the key differences between nasopharyngeal cancer, oropharyngeal cancer, and laryngeal cancer, including their causes, symptoms, diagnosis, treatment, and advances in precision medicine.
Why Are Solid Tumors More Difficult to Treat Than Blood Cancers? Uncovering the Key Challenges Behind Cancer Therapy
July 02, 2026
Discover why solid tumors are significantly more difficult to treat than blood cancers, including the roles of the tumor microenvironment, immune evasion, tumor heterogeneity, drug delivery barriers, and emerging cancer therapies.
Why Are Trispecific Antibodies More Complex Than Bispecific Antibodies? Understanding the Design Logic Behind Trispecific Antibodies
July 02, 2026
Explore why trispecific antibodies are more complex than bispecific antibodies, including their design strategies, engineering challenges, clinical potential, and future role in cancer immunotherapy.
How Does the Dual-arm Structure of T-cell Engagers Work? Unveiling the Design Logic Behind T-cell Engagers
July 01, 2026
Discover how the dual-arm structure of T-cell engagers (TCEs) redirects T cells to attack cancer cells, and explore the engineering principles, advantages, challenges, and future of T-cell engager therapies.
Is a Trispecific Antibody Necessarily Better Than a Bispecific? An Analysis of Efficacy, Safety, and Future Applications
July 01, 2026
Explore the differences between trispecific antibodies and bispecific antibodies, including efficacy, safety, manufacturing complexity, and future applications in cancer immunotherapy.
What Does Guideline Inclusion Mean? Analyzing the Demand Growth Path of Oncology Drugs
June 25, 2026
KRAS-Mutant Non-Small Cell Lung Cancer Treatment Advances: From G12C Inhibitors to Pan-RAS Therapies
June 23, 2026
When ADCs Achieve a 50% Objective Response Rate: How Technological Innovation Translates into Patient Benefit
June 23, 2026
Explore why ADC therapies achieving a 50% objective response rate are attracting global attention and how advances in ADC technology are translating into meaningful benefits for cancer patients.
ADC Enters the 3.0 Era: What Are the New Highlights of Next-Generation Cancer Therapies?
June 22, 2026
Explore the key innovations driving the ADC 3.0 era, including new targets, advanced linker technologies, novel payloads, enhanced bystander effects, and combination therapy strategies that are reshaping precision oncology.
Why Are ADC Drugs Remaining So Hot? A Comprehensive Analysis of the Global Cancer Innovation Landscape
June 22, 2026
Discover why antibody-drug conjugates (ADCs) remain one of the hottest areas in oncology innovation, from new targets and linker technologies to payload evolution, combination therapies, and China’s rapidly growing ADC ecosystem.
Mapping China’s RAS Pipeline Landscape: From “Undruggable” Target to a New Frontier in Oncology Innovation
June 22, 2026
Explore how China’s biopharmaceutical industry is building a comprehensive RAS-targeted therapy ecosystem, from KRAS G12C and KRAS G12D inhibitors to Pan-KRAS, SHP2, and SOS1 strategies, driving the next wave of precision oncology innovation.
What Has Daraxonrasib Improved Over Traditional Treatments in Third-Line Pancreatic Cancer?
June 18, 2026
Daraxonrasib (RMC-6236), a next-generation pan-RAS inhibitor, is showing encouraging survival benefits in heavily pretreated pancreatic cancer patients. Learn how it differs from traditional chemotherapy and why pan-RAS therapies are attracting global attention.
What Treatment Options Are Available for Patients with RAS-Mutant Pancreatic Cancer? A Closer Look at the Latest Progress of RMC-6236
June 18, 2026
Explore current treatment options for RAS-mutant pancreatic cancer and the latest clinical progress of RMC-6236 (Daraxonrasib), a next-generation pan-RAS inhibitor showing promising survival benefits in heavily pretreated patients.